{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:14:52Z","timestamp":1793672092587,"version":"4.5.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis explored the relationship between vancomycin (VCM) monitoring strategies and VCM effectiveness and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted our analysis using the MEDLINE, Web of Sciences, and Cochrane Register of Controlled Trials electronic databases searched on August 9, 2020. We calculated odds ratios (ORs) and 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Adult patients with methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA) bacteraemia with VCM trough concentrations \u226515\u2009\u03bcg\/mL had significantly lower treatment failure rates (OR 0.63, 95% CI 0.47\u20130.85). The incidence of acute kidney injury (AKI) increased with increased trough concentrations and was significantly higher for trough concentrations \u226520\u2009\u03bcg\/mL compared to those at 15\u201320\u2009\u03bcg\/mL (OR 2.39, 95% CI 1.78\u20133.20). Analysis of the target area under the curve\/minimum inhibitory concentration ratios (AUC\/MIC) showed significantly lower treatment failure rates for high AUC\/MIC (cut-off 400\u2009\u00b1\u200915%) (OR 0.28, 95% CI 0.18\u20130.45). The safety analysis revealed that high AUC value (cut-off 600\u2009\u00b1\u200915%) significantly increased the risk of AKI (OR 2.10, 95% CI 1.13\u20133.89). Our meta-analysis of differences in monitoring strategies included four studies. The incidence of AKI tended to be lower in AUC-guided monitoring than in trough-guided monitoring (OR 0.54, 95% CI 0.28\u20131.01); however, it was not significant in the analysis of mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified VCM trough concentrations and AUC values that correlated with effectiveness and safety. Furthermore, compared to trough-guided monitoring, AUC-guided monitoring showed potential for decreasing nephrotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-021-05858-6","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T16:03:44Z","timestamp":1612800224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":161,"title":["The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing"],"prefix":"10.1186","volume":"21","author":[{"given":"Moeko","family":"Tsutsuura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumika","family":"Osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-0670","authenticated-orcid":false,"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,6]]},"reference":[{"key":"5858_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285\u201392.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"5858_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","volume":"42","author":"DP Levine","year":"2006","unstructured":"Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42(Suppl 1):S5\u201312. https:\/\/doi.org\/10.1086\/491709.","journal-title":"Clin Infect Dis"},{"key":"5858_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0146224","volume":"11","author":"P Men","year":"2016","unstructured":"Men P, Li HB, Di Zhai S, Zhao RS. Association between the AUC0-24 \/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis. PLoS One. 2016;11:1\u201311.","journal-title":"PLoS One"},{"key":"5858_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatr. Am J Health Syst Pharm. 2020;77:835\u201364.","journal-title":"Am J Health Syst Pharm"},{"key":"5858_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","volume":"19","author":"K Matsumoto","year":"2013","unstructured":"Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19:365\u201380. https:\/\/doi.org\/10.1007\/s10156-013-0599-4.","journal-title":"J Infect Chemother"},{"key":"5858_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.cmi.2019.10.029","volume":"26","author":"BR Dalton","year":"2020","unstructured":"Dalton BR, Rajakumar I, Langevin A, Ondro C, Sabuda D, Griener TP, et al. Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity. Clin Microbiol Infect. 2020;26:436\u201346. https:\/\/doi.org\/10.1016\/j.cmi.2019.10.029.","journal-title":"Clin Microbiol Infect"},{"key":"5858_CR7","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkw254","volume":"71","author":"ZK Ye","year":"2016","unstructured":"Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society. J Antimicrob Chemother. 2016;71:3020\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"5858_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-016-2252-7","volume":"9","author":"S Tongsai","year":"2016","unstructured":"Tongsai S, Koomanachai P. The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Res Notes. 2016;9:1\u201316.","journal-title":"BMC Res Notes"},{"key":"5858_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507\u201314.","journal-title":"Clin Infect Dis"},{"key":"5858_CR10","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/jac\/dkaa184","volume":"75","author":"I Bellos","year":"2020","unstructured":"Bellos I, Daskalakis G, Pergialiotis V. Relationship of vancomycin trough levels with acute kidney injury risk: an exposure-toxicity meta-analysis. J Antimicrob Chemother. 2020;75:2725\u201334.","journal-title":"J Antimicrob Chemother"},{"key":"5858_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ Van Hal","year":"2013","unstructured":"Van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"5858_CR12","doi-asserted-by":"publisher","first-page":"e00079","DOI":"10.1128\/AAC.00079-19","volume":"63","author":"GM Pais","year":"2019","unstructured":"Pais GM, Avedissian SN, Nicholas O\u2019Donnell J, Rhodes NJ, Lodise TP, Prozialeck WC, et al. Comparative performance of urinary biomarkers for vancomycin-induced kidney injury according to timeline of injury. Antimicrob Agents Chemother. 2019;63:e00079\u201319.","journal-title":"Antimicrob Agents Chemother"},{"key":"5858_CR13","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1093\/jac\/dkz167","volume":"74","author":"SN Avedissian","year":"2019","unstructured":"Avedissian SN, Pais GM, O\u2019Donnell JN, Lodise TP, Liu J, Prozialeck WC, et al. Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. J Antimicrob Chemother. 2019;74:2326\u201334.","journal-title":"J Antimicrob Chemother"},{"key":"5858_CR14","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/cid\/ciz051","volume":"69","author":"DM Aljefri","year":"2019","unstructured":"Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69:1881\u20137.","journal-title":"Clin Infect Dis"},{"key":"5858_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/phar.2234","volume":"39","author":"L Meng","year":"2019","unstructured":"Meng L, Wong T, Huang S, Mui E, Nguyen V, Espinosa G, et al. Conversion from vancomycin trough concentration\u2013guided dosing to area under the curve\u2013guided dosing using two sample measurements in adults: implementation at an Academic Medical Center. Pharmacotherapy. 2019;39:433\u201342.","journal-title":"Pharmacotherapy."},{"key":"5858_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jpids\/piz036","volume":"9","author":"J Olson","year":"2019","unstructured":"Olson J, Hersh AL, Sorensen J, Zobell J, Anderson C, Thorell EA. Intravenous vancomycin therapeutic drug monitoring in children: evaluation of a pharmacy-driven protocol and collaborative practice agreement. J Pediatric Infect Dis Soc. 2019;9:334\u201341.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"5858_CR17","volume-title":"Cochrane Handbook for systematic reviews of interventions version 5.1.0 (updated March 2011)","author":"J Higgins","year":"2011","unstructured":"Higgins J. Cochrane Handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). 2011. http:\/\/training.cochrane.org\/handbook."},{"key":"5858_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1517\/14740330903413514","volume":"9","author":"ED Hermsen","year":"2010","unstructured":"Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010;9:9\u201314.","journal-title":"Expert Opin Drug Saf"},{"key":"5858_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.diagmicrobio.2011.08.002","volume":"71","author":"EC Clemens","year":"2011","unstructured":"Clemens EC, Chan JD, Lynch JB, Dellit TH. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2011;71:408\u201314. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2011.08.002.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"5858_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/cir124","volume":"52","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975\u201381. https:\/\/doi.org\/10.1093\/cid\/cir124.","journal-title":"Clin Infect Dis"},{"key":"5858_CR21","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1128\/AAC.00380-13","volume":"57","author":"AM Casapao","year":"2013","unstructured":"Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate staphylococcus aureus bloodstream infection. Antimicrob Agents Chemother. 2013;57:4252\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"5858_CR22","doi-asserted-by":"publisher","first-page":"O1098","DOI":"10.1111\/1469-0691.12695","volume":"20","author":"N Ghosh","year":"2014","unstructured":"Ghosh N, Chavada R, Maley M, van Hal SJ. Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2014;20:O1098\u2013105.","journal-title":"Clin Microbiol Infect"},{"key":"5858_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ijantimicag.2015.09.010","volume":"46","author":"KH Song","year":"2015","unstructured":"Song KH, Bin KH, Kim HS, Lee MJ, Jung Y, Kim G, et al. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2015;46:689\u201395.","journal-title":"Int J Antimicrob Agents"},{"key":"5858_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0193585","volume":"13","author":"CF Fu","year":"2018","unstructured":"Fu CF, Da Huang J, Wang JT, Lin SW, Wu CC. The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia. PLoS One. 2018;13:1\u201310.","journal-title":"PLoS One"},{"key":"5858_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","volume":"52","author":"BT Mogle","year":"2018","unstructured":"Mogle BT, Steele JM, Seabury RW, Dang UJ, Kufel WD. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2018;52:805\u201310. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.08.024.","journal-title":"Int J Antimicrob Agents"},{"key":"5858_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/IDR.S109485","volume":"9","author":"R Hirano","year":"2016","unstructured":"Hirano R, Sakamoto Y, Kitazawa J, Yamamoto S, Tachibana N. Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience. Infect Drug Resist. 2016;9:243\u201352.","journal-title":"Infect Drug Resist"},{"key":"5858_CR27","volume-title":"Relationship between initial vancomycin trough levels and early-onset vancomycin-associated nephrotoxicity in critically ill patients","author":"M Chuma","year":"2018","unstructured":"Chuma M, Makishima M, Imai T, Tochikura N, Suzuki S, Kuwana T, et al. Relationship between initial vancomycin trough levels and early-onset vancomycin-associated nephrotoxicity in critically ill patients. 2018."},{"key":"5858_CR28","first-page":"349","volume":"21","author":"M Huang","year":"2018","unstructured":"Huang M, Wu H, Zhou J, Xu M, Zhou S. Efficacy of vancomycin on gram-positive bacterial infection in elderly critical patients and risk factors associated with nephrotoxicity. Arch Iran Med. 2018;21:349\u201355.","journal-title":"Arch Iran Med"},{"key":"5858_CR29","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s11096-018-0634-8","volume":"40","author":"SJ Park","year":"2018","unstructured":"Park SJ, Lim NR, Park HJ, Yang JW, Kim MJ, Kim K, et al. Evaluation of risk factors for vancomycin-induced nephrotoxicity. Int J Clin Pharm. 2018;40:1328\u201334. https:\/\/doi.org\/10.1007\/s11096-018-0634-8.","journal-title":"Int J Clin Pharm"},{"key":"5858_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2147\/IDR.S159447","volume":"11","author":"N Shime","year":"2018","unstructured":"Shime N, Saito N, Bokui M, Sakane N, Kamimura M, Shinohara T, et al. Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections. Infect Drug Resist. 2018;11:1073\u201381.","journal-title":"Infect Drug Resist"},{"key":"5858_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0222095","volume":"14","author":"CDC de Almeida","year":"2019","unstructured":"de Almeida CDC, Sim\u00f5es e Silva AC, de Queiroz Oliveira JA, Fonseca Batista IS, Pereira FH, Gon\u00e7alves JE, et al. Vancomycin-associated nephrotoxicity in non-critically ill patients admitted in a Brazilian public hospital: a prospective cohort study. PLoS One. 2019;14:1\u201314.","journal-title":"PLoS One"},{"key":"5858_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clinthera.2011.12.013","volume":"34","author":"EL Cano","year":"2012","unstructured":"Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin Ther. 2012;34:149\u201357. https:\/\/doi.org\/10.1016\/j.clinthera.2011.12.013.","journal-title":"Clin Ther"},{"key":"5858_CR33","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1345\/aph.1R158","volume":"46","author":"A Horey","year":"2012","unstructured":"Horey A, Mergenhagen KA, Mattappallil A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran\u2019s population: a retrospective analysis. Ann Pharmacother. 2012;46:1477\u201383.","journal-title":"Ann Pharmacother"},{"key":"5858_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jhm.946","volume":"7","author":"KK Prabaker","year":"2012","unstructured":"Prabaker KK, Tran TPH, Pratummas T, Goetz MB, Graber CJ. Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J Hosp Med. 2012;7:91\u20137.","journal-title":"J Hosp Med"},{"key":"5858_CR35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000356756","volume":"59","author":"S Fujii","year":"2014","unstructured":"Fujii S, Takahashi S, Makino S, Kunimoto Y, Nakata H, Noda N, et al. Impact of vancomycin or linezolid therapy on development of renal dysfunction and thrombocytopenia in Japanese patients. Chemotherapy. 2014;59:319\u201324.","journal-title":"Chemotherapy."},{"key":"5858_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jss.2013.04.047","volume":"184","author":"EJ Ley","year":"2013","unstructured":"Ley EJ, Liou DZ, Singer MB, Mirocha J, Srour M, Bukur M, et al. Supratherapeutic vancomycin levels after trauma predict acute kidney injury and mortality. J Surg Res. 2013;184:501\u20136. https:\/\/doi.org\/10.1016\/j.jss.2013.04.047.","journal-title":"J Surg Res"},{"key":"5858_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-14-183","volume":"14","author":"SL Barriere","year":"2014","unstructured":"Barriere SL, Stryjewski ME, Corey GR, Genter FC, Rubinstein E. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the phase 3 ATTAIN studies. BMC Infect Dis. 2014;14:1\u20135.","journal-title":"BMC Infect Dis"},{"key":"5858_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5935\/0103-507X.20160071","volume":"28","author":"VY Obara","year":"2016","unstructured":"Obara VY, Zacas CP, De Maio Carrilho CMD, Delfino VDA. Currently used dosage regimens of vancomycin fail to achieve therapeutic levels in approximately 40% of intensive care unit patients. Rev Bras Ter Intensiva. 2016;28:380\u20136.","journal-title":"Rev Bras Ter Intensiva"},{"key":"5858_CR39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000452427","volume":"44","author":"K Hammoud","year":"2016","unstructured":"Hammoud K, Brimacombe M, Yu A, Goodloe N, Haidar W, El Atrouni W. Vancomycin trough and acute kidney injury: a large retrospective, cohort study. Am J Nephrol. 2016;44:456\u201361.","journal-title":"Am J Nephrol"},{"key":"5858_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ijantimicag.2012.10.015","volume":"41","author":"S Zelenitsky","year":"2013","unstructured":"Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013;41:255\u201360. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.10.015.","journal-title":"Int J Antimicrob Agents"},{"key":"5858_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijantimicag.2013.10.017","volume":"43","author":"Y Jung","year":"2014","unstructured":"Jung Y, Song KH, Cho JE, Kim HS, Kim NH, Kim TS, et al. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2014;43:179\u201383.","journal-title":"Int J Antimicrob Agents"},{"key":"5858_CR42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5114\/ait.2019.87362","volume":"51","author":"M Makmor-Bakry","year":"2019","unstructured":"Makmor-Bakry M, Ahmat ANMF, Shamsuddin AF, Lau CL, Ramli R. Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients. Anaesthesiol Intensive Ther. 2019;51:218\u201323.","journal-title":"Anaesthesiol Intensive Ther"},{"key":"5858_CR43","doi-asserted-by":"publisher","first-page":"e02535","DOI":"10.1128\/AAC.02535-16","volume":"61","author":"R Chavada","year":"2017","unstructured":"Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hald SJ. Establishment of an AUC0\u201324 threshold for nephrotoxicity is a step towards individualized vancomycin dosing for methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2017;61:e02535\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"5858_CR44","doi-asserted-by":"publisher","first-page":"e01684","DOI":"10.1128\/AAC.01684-17","volume":"62","author":"EJ Zasowski","year":"2018","unstructured":"Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, et al. Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin. Antimicrob Agents Chemother. 2018;62:e01684\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"5858_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-020-00354-2","volume":"19","author":"L Brunetti","year":"2020","unstructured":"Brunetti L, Song JH, Suh D, Kim HJ, Seong YH, Lee DS, et al. The risk of vancomycin toxicity in patients with liver impairment. Ann Clin Microbiol Antimicrob. 2020;19:1\u20139. https:\/\/doi.org\/10.1186\/s12941-020-00354-2.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"5858_CR46","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/cid\/ciz460","volume":"70","author":"TP Lodise","year":"2020","unstructured":"Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, et al. The emperor\u2019s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE). Clin Infect Dis. 2020;70:1536\u201345.","journal-title":"Clin Infect Dis"},{"key":"5858_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01293-17","volume":"61","author":"NA Finch","year":"2017","unstructured":"Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017;61:1\u201310. https:\/\/doi.org\/10.1128\/AAC.01293-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"5858_CR48","doi-asserted-by":"publisher","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","volume":"62","author":"MN Neely","year":"2018","unstructured":"Neely MN, Kato L, Youn G, Kraler L, Bayard D, Van Guilder M, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62:e02042\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"5858_CR49","doi-asserted-by":"publisher","unstructured":"Oda K, Jono H, Nosaka K, Saito H. Reduced nephrotoxicity in vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15\u201320 \u03bcg\/mL concentration. Int J Antimicrob Agents. 2020:106109. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106109.","DOI":"10.1016\/j.ijantimicag.2020.106109"},{"key":"5858_CR50","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/ggi.12739","volume":"17","author":"Y Enomoto","year":"2017","unstructured":"Enomoto Y, Yokomura K, Hasegawa H, Ozawa Y, Matsui T, Suda T. Healthcare-associated pneumonia with positive respiratory methicillin-resistant Staphylococcus aureus culture: predictors of the true pathogenicity. Geriatr Gerontol Int. 2017;17:456\u201362.","journal-title":"Geriatr Gerontol Int"},{"key":"5858_CR51","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/resp.12288","volume":"19","author":"K Nagaoka","year":"2014","unstructured":"Nagaoka K, Yanagihara K, Harada Y, Yamada K, Migiyama Y, Morinaga Y, et al. Predictors of the pathogenicity of methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Respirology. 2014;19:556\u201362.","journal-title":"Respirology."},{"key":"5858_CR52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00540-007-0600-4","volume":"22","author":"M Sakaguchi","year":"2008","unstructured":"Sakaguchi M, Shime N, Fujita N, Fujiki S, Hashimoto S. Current problems in the diagnosis and treatment of hospital-acquired methicillin-resistant Staphylococcus aureus pneumonia. J Anesth. 2008;22:125\u201330.","journal-title":"J Anesth"},{"key":"5858_CR53","doi-asserted-by":"publisher","unstructured":"Kawanami T, Yatera K, Yamasaki K, Noguchi S, Fukuda K, Akata K, et al. Clinical impact of methicillin-resistant staphylococcus aureus on bacterial pneumonia: cultivation and 16S ribosomal RNA gene analysis of bronchoalveolar lavage fluid. BMC Infect Dis. 2016;16. https:\/\/doi.org\/10.1186\/s12879-016-1493-3.","DOI":"10.1186\/s12879-016-1493-3"},{"key":"5858_CR54","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ Van Hal","year":"2012","unstructured":"Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755\u201371.","journal-title":"Clin Infect Dis"},{"key":"5858_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01293-17","volume":"61","author":"NA Finch","year":"2017","unstructured":"Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, et al. A quasi-experiment to study the impact of vancomycin area under the nephrotoxicity. Antimicrob Agents Chemother. 2017;61:1\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"5858_CR56","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/FTD.0000000000000622","volume":"41","author":"L Clark","year":"2019","unstructured":"Clark L, Skrupky LP, Servais R, Brummitt CF, Dilworth TJ. Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented Staphylococcal infections. Ther Drug Monit. 2019;41:483\u20138.","journal-title":"Ther Drug Monit"},{"key":"5858_CR57","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000359","volume":"39","author":"AB Kamel","year":"2017","unstructured":"Kamel AB, Bourguignon L, Marcos M, Ducher M, Goutelle S. Is trough concentration of vancomycin predictive of the area under the curve? A clinical study in elderly patients. Ther Drug Monit. 2017;39:83\u20137.","journal-title":"Ther Drug Monit"},{"key":"5858_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","volume":"77","author":"MP Pai","year":"2014","unstructured":"Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50\u20137. https:\/\/doi.org\/10.1016\/j.addr.2014.05.016.","journal-title":"Adv Drug Deliv Rev"},{"key":"5858_CR59","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/AAC.01653-13","volume":"58","author":"MN Neely","year":"2014","unstructured":"Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother. 2014;58:309\u201316.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05858-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-05858-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05858-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T21:04:16Z","timestamp":1674939856000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05858-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,6]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["5858"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05858-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,6]]},"assertion":[{"value":"26 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MT, HM, NK, YM, ST, SO, YE, KT, SF, YT1, YH, and TK report no conflicts of interest. YT2 received research grants from Dainippon Sumitomo Pharm Co., Ltd., Astellas Pharm, Inc., and MSD Japan. KM received a research grant from Meiji Seika Pharma Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}